MEI Pharma Stock News

We're checking in on the latest penny stocks news for today with two companies that investors are watching fall on Friday! The post Penny Stocks Today: Why MEIP and HNST Are Plunging Friday appeared f

MEI Pharma Inc (NASDAQ: MEIP) shares are plunging in Thursday's after-hours session after the company provided an investor update following a recent meeting with the U.S. Food and Drug Administration

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that two abstracts highlighting data from two oncology drug candidates in its pipeline will be presented at the upcoming American Association for Cancer Research Annual Meeting 2022 to be held April 8 – 13, 2022. Details of the poster presentations: Title: Efficacy and immune profiling of the PI3K delta inhibitor zandelisib (ME-401) in a

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 31.58% and 139.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

MEI Pharma press release (MEIP): FQ2 GAAP EPS of -$0.09.Revenue of $18.22M (+98.7% Y/Y).

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended December 31, 2021, and highlighted recent corporate progress. The next few quarters have the makings for a potentially transformational period for MEI Pharma, headlined by complete Phase 2 TIDAL data in follicular lymphoma later in the year, which we believe will provide the foundation to support our plan to

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 31.58% and 139.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the expansion of its management team with the addition of two experienced industry executives. Alejandro Ricart, M.D., joins MEI as senior vice president, clinical development, a role that will report to Richard Ghalie, M.D., chief medical officer, and Yomara Gomez-Naiden joins as senior vice president, quality, reporting to Daniel P. Go

Upgrades BTIG upgraded the previous rating for Insulet Corp (NASDAQ:PODD) from Neutral to Buy. For the third quarter, Insulet had an EPS of $0.18, compared to year-ago quarter EPS of $0.17. The stock

MEI Pharma, Inc. (MEIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

In the last trading session, 2.38 million shares of the MEI Pharma Inc. (NASDAQ:MEIP) were traded, and its beta was 1.43. Most recently the company’s share price was $2.51, and it changed around -$0.07 or -2.71% from the last close, which brings the market valuation of the company to $304.31M. MEIP currently trades at a … It’s Easy To Bet On MEI Pharma Inc. (NASDAQ: MEIP) For Economic Progress Over The Impending Months Read More »

Brokerages expect MEI Pharma, Inc. (NASDAQ:MEIP) to report $7.62 million in sales for the current quarter, according to Zacks. Three analysts have made estimates for MEI Pharmas earnings, with the lowest sales estimate coming in at $2.20 million and the highest estimate coming in at $13.40 million. MEI Pharma reported sales of $9.17 million during []

MEI Pharma, Inc. (NASDAQ:MEIP) Research analysts at Truist Securiti upped their Q2 2022 earnings per share (EPS) estimates for MEI Pharma in a report issued on Sunday, December 5th. Truist Securiti analyst R. Karnauskas now anticipates that the company will post earnings of ($0.22) per share for the quarter, up from their prior forecast []

Shares of MEI Pharma, Inc. (NASDAQ:MEIP) have earned a consensus rating of Buy from the six analysts that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12 month target price among analysts that []